AQEMIA
28.6.2024 07:31:26 CEST | Business Wire | Press release
AQEMIA, a leading company in generative-AI-driven drug discovery, announces the achievement of a research milestone in its collaboration with Servier, an international independent pharmaceutical company, to address an undruggable target in immuno-oncology.
Based on AQEMIA ‘s quantum and statistical physics-based calculations, and within the span of a few months, a series of molecules experimentally active on an undruggable target in immuno-oncology have been successfully identified. This milestone triggers an undisclosed payment to AQEMIA.
"Our teams are very proud of this achievement that demonstrates the power of AQEMIA's cutting-edge generative AI and deep physics in creating novel, patentable molecules to meet therapeutic needs that are still immense, particularly in the field of immuno-oncology. Within the framework of our collaboration with Servier, we have reached the stage where a series of molecules are subsequently proven impactful in vitro and in vivo assays. " said Maximilien Levesque, PhD, CEO and Co-founder of AQEMIA.
This critical milestone is a continuation of Servier and AQEMIA’s successful partnership program, initiated in December 2021, to accelerate drug candidate discovery in immuno-oncology using artificial intelligence and deep physics.
AQEMIA has worked on more than a dozen in-house therapeutic programs in oncology and immuno-oncology, as well as in new therapeutic areas such as immunology, inflammation and diseases of the central nervous system. To date, AQEMIA’s three most advanced programs are being tested against cancers in animals.
About AQEMIA
AQEMIA is a next-gen techbio generating one of the world's fastest-growing drug discovery pipeline. Our mission is to design fast many innovative drug candidates for critical diseases. Our differentiation lies in our unique quantum and statistical mechanics algorithms to power a generative artificial intelligence designing novel drug candidates, without the need to train on experimental data. We already delivered several drug discovery successes in internal pipeline as well as in collaboration with Pharma companies - most advanced programs being currently in vivo optimization.
For more information, visit AQEMIA.com and our LinkedIn
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240627468833/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
EdgeConneX Looks to Enter Swedish Market as Part of European Data Center Expansion Strategy27.2.2026 08:05:00 CET | Press release
Planned data center campus in Skellefteå would support future AI and cloud infrastructure needs EdgeConneX®, an EQT portfolio company with an extensive Pan-European data center footprint, looks to expand its presence with a new site located in Skellefteå, Sweden. The data center site will be acquired from Lyten, a global company that specializes in lithium-sulfur batteries and energy storage. The site would support EdgeConneX broader strategy to expand digital infrastructure capacity across the Nordics. Subject to the completion of applicable administrative and regulatory processes, EdgeConneX will look to develop a data center campus with potential capacity of up to one gigawatt in support of future AI and cloud computing workloads. Upon completion, the data center campus would be one of the largest facilities in Europe that would be primarily powered by renewable energy. “Sweden represents an attractive long‑term market for digital infrastructure investment. The country’s access to r
Lyten Completes Acquisition of Northvolt Sweden and Establishes its First Lyten Industrial Hub in Sweden27.2.2026 08:00:00 CET | Press release
Lyten announces it has completed the acquisition of Northvolt’s battery assets in Sweden, totaling nearly $5B in value.The Skellefteå battery site, Northvolt Ett, is resuming operations and plans to deliver commercial cells in 2H 2026.Lyten announces the establishment of the Lyten Industrial Hub in Skellefteå, Sweden to co-locate battery manufacturing, data centers, and additional manufacturing activities.In connection with the closing, EdgeConneX, a portfolio company of EQT, plans to acquire a data center site from Lyten, with potential capacity of up to one gigawatt. Lyten, a global leader in lithium-sulfur batteries and energy storage, announced today that it has completed the acquisition of Northvolt Ett and Ett Expansion (Skellefteå, Sweden) and Northvolt Labs (Västerås, Sweden). The Northvolt Sweden acquisition includes 16 GWh of existing battery manufacturing capacity, more than 160 hectares of land, infrastructure and buildings to support expanded manufacturing and industrial a
SOLUM and Competera Expand Partnership to Integrate AI-Driven Pricing Solutions with Real-Time ESL Execution Across Europe27.2.2026 08:00:00 CET | Press release
SOLUM (KOSPI: 248070) and Competera announced the expansion of their strategic partnership to further connect AI-driven pricing intelligence with real-time Electronic Shelf Label (ESL) execution across European retail networks. The announcement follows strong engagement at EuroShop, where the integrated solution attracted significant interest from the local retail operators. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260226065052/en/ SOLUM and Competera announced the expansion of their strategic partnership (Image: SOLUM) The collaboration brings together Competera’s AI-driven pricing solutions for enterprise retail with SOLUM’s Newton ESL platform, enabling retailers to align advanced price optimization with synchronized shelf-edge communication. Competera’s platform applies machine learning and advanced analytics to help retailers balance competitiveness and value-based pricing, strengthen customer loyalty, improve pri
OpenSynergy's Blue SDK Now Drives More Than 400 Million Cars27.2.2026 08:00:00 CET | Press release
OpenSynergy's Blue SDK, the industry-leading independent Bluetooth® stack, is now deployed in over 400 million cars. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260226654887/en/ OpenSynergy's Blue SDK now drives more than 400 million cars OpenSynergy is thrilled and very proud to announce that Blue SDK is now integrated in more than an estimated 400 million cars worldwide, deployed by virtually all the major OEMs across a wide range of vehicles, segments, and markets, offering extensive and consistent interoperability between many generations of smartphones and cars. “This is an incredible milestone for OpenSynergy, but it is also a testament to the ubiquity of the Bluetooth standard in our everyday lives and the success of the entire Bluetooth ecosystem under the leadership of the Bluetooth SIG,” comments Kathleen Ende, CEO, OpenSynergy. “Blue SDK is now an essential part of the daily automotivecockpit plug and play expe
Galderma’s Nemluvio® (nemolizumab) Demonstrates Long-Term Disease Control in Prurigo Nodularis up to Three Years27.2.2026 07:00:00 CET | Press release
Results from an interim analysis of the OLYMPIA long-term extension (LTE) study show that Nemluvio maintained long-term disease control up to three years, with clinically meaningful improvements in itch intensity, skin lesions and quality of life1 These results, to be presented at 2026 Winter Clinical™ Miami, mark the longest LTE study in prurigo nodularis reported to date1 Nemluvio is the first approved monoclonal antibody that specifically targets and inhibits the signaling of IL-31 – a neuroimmune cytokine that drives itch and other symptoms in prurigo nodularis2-5 Nemluvio is approved by multiple regulatory authorities around the world for the treatment of prurigo nodularis and moderate-to-severe atopic dermatitis, including in the United States (U.S.) and European Union (EU)4,5 Galderma (SIX: GALD) today announced new data from the OLYMPIA open-label extension study investigating the long-term safety and efficacy of Nemluvio in moderate-to-severe prurigo nodularis.1 Results showed
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom